CU01 – Diabetic Nephropathy
MOA of CU01 : Nrf2 activation & inhibition of TGF- β/Smad signaling
Dual Mechanism of Action:
NRF2 activation + TGF-β inhibition, targeting
oxidative stress and fibrosis
simultaneously.
Phase 2a demonstrated safety and improved glomerular filtration rate (GFR).
Ph2b results of CU01
Completed the Phase 2b for Diabetic Nephropathy.
Conducted in 240 patients in Korea
High Unmet Need
Offers a potential new option in DN and CKD, where current treatments remain limited
Dual Mechanism of Action
NRF2 activation + TGF-β inhibition, targeting oxidative stress and fibrosis simultaneously
Phase 2a demonstrated safety and improved glomerular filtration rate (GFR)